By ThinkSabio #ThinkSabio Latest News
Company Description: Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally
News: $INDV $10.28 Indivior’s SUBLOCADE Prior Approval Supplement Receives FDA Priority Review With PDUFA Date Set For Feb 7, 2025